A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03864627 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
33
Enrollment
INDUSTRY
Sponsor class

Stopped MOR106 clinical development in atopic dermatitis was stopped for futility

Conditions

Interventions

Sponsor

Lakefront Biotherapeutics NV